Literature DB >> 28882322

Who Can Diagnose Parkinson's Disease First? Role of Pre-motor Symptoms.

Mayela Rodríguez-Violante1, Rosalía Zerón-Martínez2, Amin Cervantes-Arriaga3, Teresa Corona4.   

Abstract

In 1817, James Parkinson described the disease which bears his name. The disease was defined as a neurological syndrome characterized by tremor, rigidity, and slowness of movements. Almost one hundred years later, degeneration of neurons in the substantia nigra and low levels of dopamine were identified as the putative cause of the disease, thus the disease remained as a pure neurological disorder. In the late 1990s, non-motor symptoms of the disease began to gain interest because of their clinical relevance, as well as for their potential role in broadening the understanding of the pathophysiological mechanisms involved. In the last decade, focus has shifted to the pre-motor symptoms, those non-motor symptoms that present years before the motor onset of the disease. The main premotor symptoms include rapid eye movement sleep behavior disorder, hyposmia, constipation and depression. Subjects with these symptoms usually are not initially seen by a neurologist, and by the time they are consulted neuronal loss in the substantia nigra is over 50%. This review summarizes the overall relevance of non-motor symptoms, their frequency and their pathophysiological implications. Also, the importance of pre-motor symptoms, and the role of specialists other than neurologists in diagnosing subjects with Parkinson's disease is discussed. Two hundred years after the first description of the disease, it is now evident that Parkinson's disease is a systemic disease and a multispecialty team approach is mandatory.
Copyright © 2017 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Non-motor; Parkinson's disease; Pre-motor

Mesh:

Year:  2017        PMID: 28882322     DOI: 10.1016/j.arcmed.2017.08.005

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  7 in total

Review 1.  Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.

Authors:  Mariza Bortolanza; Glauce C Nascimento; Sergio B Socias; Diego Ploper; Rosana N Chehín; Rita Raisman-Vozari; Elaine Del-Bel
Journal:  J Neural Transm (Vienna)       Date:  2018-08-14       Impact factor: 3.575

2.  Validation of Cognitive Rehabilitation as a Balance Rehabilitation Strategy in Patients with Parkinson's Disease: Study Protocol for a Randomized Controlled Trial.

Authors:  Aida Arroyo-Ferrer; Francisco José Sánchez-Cuesta; Yeray González-Zamorano; María Dolores Del Castillo; Carolina Sastre-Barrios; Marcos Ríos-Lago; Juan Pablo Romero
Journal:  Medicina (Kaunas)       Date:  2021-03-26       Impact factor: 2.430

Review 3.  Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.

Authors:  Michael J Beckstead; Rebecca D Howell
Journal:  Exp Neurol       Date:  2021-03-20       Impact factor: 5.620

4.  Urological dysfunctions in patients with Parkinson's disease: clues from clinical and non-invasive urological assessment.

Authors:  Francesca Valentino; Tommaso Vincenzo Bartolotta; Giuseppe Cosentino; Sergio Mastrilli; Valentina Arnao; Paolo Aridon; Salvatore Scurria; Alice Pavone; Carlo Pavone; Marco D'Amelio
Journal:  BMC Neurol       Date:  2018-09-20       Impact factor: 2.474

5.  Anatomical Templates of the Midbrain Ventral Tegmental Area and Substantia Nigra for Asian Populations.

Authors:  Yuko Nakamura; Naohiro Okada; Akira Kunimatsu; Kiyoto Kasai; Shinsuke Koike
Journal:  Front Psychiatry       Date:  2018-08-28       Impact factor: 4.157

Review 6.  Forestalling the Epidemics of Parkinson's Disease Through Plant-Based Remedies.

Authors:  Ines Banjari; Tihana Marček; Svetlana Tomić; Viduranga Y Waisundara
Journal:  Front Nutr       Date:  2018-10-30

Review 7.  The Challenge and Opportunity to Diagnose Parkinson's Disease in Midlife.

Authors:  Alexander Kilzheimer; Thomas Hentrich; Simone Burkhardt; Julia M Schulze-Hentrich
Journal:  Front Neurol       Date:  2019-12-17       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.